Your browser doesn't support javascript.
loading
Suggested new breakpoints of anti-MERS-CoV antibody ELISA titers: performance analysis of serologic tests.
Ko, J-H; Müller, M A; Seok, H; Park, G E; Lee, J Y; Cho, S Y; Ha, Y E; Baek, J Y; Kim, S H; Kang, J-M; Kim, Y-J; Jo, I J; Chung, C R; Hahn, M-J; Drosten, C; Kang, C-I; Chung, D R; Song, J-H; Kang, E-S; Peck, K R.
Afiliação
  • Ko JH; Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Republic of Korea.
  • Müller MA; Division of Infectious Diseases, Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, South Korea.
  • Seok H; Institute of Virology, Charité - Universitätsmedizin Berlin, Helmut-Ruska-Haus Charitéplatz 1, 10117, Berlin, Germany.
  • Park GE; German Centre for Infection Research, Braunschweig, Germany.
  • Lee JY; Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Republic of Korea.
  • Cho SY; Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Republic of Korea.
  • Ha YE; Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Republic of Korea.
  • Baek JY; Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Republic of Korea.
  • Kim SH; Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Republic of Korea.
  • Kang JM; Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea.
  • Kim YJ; Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea.
  • Jo IJ; Division of Infectious Diseases, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Chung CR; Division of Infectious Diseases, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Hahn MJ; Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Drosten C; Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Kang CI; Department of Molecular Cell Biology, Center for Molecular Medicine, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, 440-746, South Korea.
  • Chung DR; Institute of Virology, Charité - Universitätsmedizin Berlin, Helmut-Ruska-Haus Charitéplatz 1, 10117, Berlin, Germany.
  • Song JH; German Centre for Infection Research, Braunschweig, Germany.
  • Kang ES; Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Republic of Korea.
  • Peck KR; Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Republic of Korea.
Eur J Clin Microbiol Infect Dis ; 36(11): 2179-2186, 2017 Nov.
Article em En | MEDLINE | ID: mdl-28695355
To provide optimal cut-off values of anti-Middle East respiratory syndrome coronavirus (MERS-CoV) serologic tests, we evaluated performance of ELISA IgG, ELISA IgA, IFA IgM, and IFA IgG using 138 serum samples of 49 MERS-CoV-infected patients and 219 serum samples of 219 rRT-PCR-negative MERS-CoV-exposed healthcare personnel and patients. The performance analysis was conducted for two different purposes: (1) prediction of neutralization activity in MERS-CoV-infected patients, and (2) epidemiologic surveillance of MERS-CoV infections among MERS-CoV-exposed individuals. To evaluate performance according to serum collection time, we used 'days post onset of illness (dpoi)' and 'days post exposure (dpex)' assessing neutralization activity and infection diagnosis, respectively. Performance of serologic tests improved with delayed sampling time, being maximized after a seroconversion period. In predicting neutralization activity, ELISA IgG tests showed optimal performance using sera collected after 21 dpoi at cut-off values of OD ratio 0.4 (sensitivity 100% and specificity 100%), and ELISA IgA showed optimal performance using sera collected after 14 dpoi at cut-off value of OD ratio 0.2 (sensitivity 85.2% and specificity 100%). In diagnosis of MERS-CoV infection, ELISA IgG exhibited optimal performance using sera collected after 28 dpex, at a cut-off value of OD ratio 0.2 (sensitivity 97.3% and specificity 92.9%). These new breakpoints are markedly lower than previously suggested values (ELISA IgG OD ratio 1.1, sensitivity 34.8% and specificity 100% in the present data set), and the performance data help serologic tests to be practically used in the field of MERS management.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaio de Imunoadsorção Enzimática / Testes Sorológicos / Infecções por Coronavirus / Coronavírus da Síndrome Respiratória do Oriente Médio / Anticorpos Antivirais Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaio de Imunoadsorção Enzimática / Testes Sorológicos / Infecções por Coronavirus / Coronavírus da Síndrome Respiratória do Oriente Médio / Anticorpos Antivirais Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article